Expression of A and B subunits of Shiga-like toxin II as fusions with glutathione S-transferase and their potential for use in seroepidemiology

We used the plasmid vector pGEX-2T for the expression of recombinant subunits of Shiga-like toxin II (SLT-II). The 5' terminus of the genes that code for either the SLT-IIA or SLT-IIB subunits was genetically fused to the 3' terminus of the gene coding for the enzyme glutathione S-transferase, which serves as a carrier in this expression system. The subunit genes were constructed synthetically by polymerase chain reaction, with appropriate restriction sites to permit in-frame downstream insertion of the genes. The resulting plasmids containing the A and B subunit genes were designated pFG1 and pFG2, respectively. Induction of Escherichia coli laboratory strains harboring pFG1 with isopropyl-beta-D-thiogalactopyranoside (IPTG) yielding only small quantities of SLT-IIA fusion proteins. Since IPTG induction was lethal for cells harboring pFG2, we constructed the recombinant plasmid pFG4, which contained a subgenic fragment of slt-IIB but without the 5' signal sequence. With this construct we were able to express very large quantities of a 33.5-kDa fusion protein, which was purified by affinity chromatography on immobilized glutathione and used as an antigen in immunoblot analysis. Rabbit serum against native SLT-II, as well as all of 12 serum samples with high neutralizing activity against SLT-II, reacted with SLT-IIB purified from an E. coli pFG4 expression system, whereas only 3 of 208 human serum samples with low neutralization titers and none of 54 serum samples with no SLT-II-neutralizing capability reacted. Failure of specific reactivity with the SLT-IIB fusion protein in the majority of human serum samples with low neutralizing activity suggests that serum factors other than immunoglobulins may be responsible for neutralizing activity in these cases. The immunoblot assay with recombinant SLT-IIB as the antigen can be recommended for use in a diagnostic setting as a simple and reliable approach to detect specific human serum antibodies to SLT-II.

[1]  H. König,et al.  The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: Results of a Central European, multicentre study , 1993, Epidemiology and Infection.

[2]  J. Brown,et al.  Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery , 1992, Journal of clinical microbiology.

[3]  F. Gunzer,et al.  Molecular detection of sorbitol-fermenting Escherichia coli O157 in patients with hemolytic-uremic syndrome , 1992, Journal of clinical microbiology.

[4]  H. Karch,et al.  Indirect hemagglutination assay for diagnosis of Escherichia coli O157 infection in patients with hemolytic-uremic syndrome , 1992, Journal of clinical microbiology.

[5]  F. Gunzer,et al.  Molecular Detection ofSorbitol-Fermenting Escherichia coli 0157inPatients withHemolytic-Uremic Syndrome , 1992 .

[6]  M. P. Jackson,et al.  Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. , 1992, Current topics in microbiology and immunology.

[7]  C. Gyles,et al.  Immunization of pigs with a purified Shiga-like toxin II variant toxoid. , 1991, Veterinary microbiology.

[8]  E. Fikrig,et al.  Molecular characterization of the humoral response to the 41-kilodalton flagellar antigen of Borrelia burgdorferi, the Lyme disease agent , 1991, Infection and immunity.

[9]  M. McKee,et al.  Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511 , 1991, Infection and immunity.

[10]  C. Lingwood,et al.  Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1 , 1990, Journal of clinical microbiology.

[11]  H. Karch,et al.  Single primer pair for amplifying segments of distinct Shiga-like-toxin genes by polymerase chain reaction , 1989, Journal of clinical microbiology.

[12]  B. Rowe,et al.  Serum antibodies to Escherichia coli serotype O157:H7 in patients with hemolytic uremic syndrome , 1989, Journal of clinical microbiology.

[13]  M. Karmali,et al.  Infection by verocytotoxin-producing Escherichia coli , 1989, Clinical Microbiology Reviews.

[14]  L. Pickering,et al.  Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome. , 1988, The Journal of pediatrics.

[15]  A. O’Brien,et al.  Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay , 1988, Journal of clinical microbiology.

[16]  H. Karch,et al.  Purified verotoxins of Escherichia coli O157:H7 decrease prostacyclin synthesis by endothelial cells. , 1988, Microbial pathogenesis.

[17]  H. Schägger,et al.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. , 1987, Analytical biochemistry.

[18]  C. Richardson,et al.  DNA sequence analysis with a modified bacteriophage T7 DNA polymerase. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. Rowe,et al.  Cloning of genes determining the production of vero cytotoxin by Escherichia coli. , 1985, Journal of general microbiology.

[20]  H. Lior,et al.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. , 1985, The Journal of infectious diseases.

[21]  N. Tolbert,et al.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. , 1978, Analytical biochemistry.

[22]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Richardson,et al.  DNA sequence analysis with a modified bacteriophage T 7 DNA polymerase ( DNA polymerase I / reverse transcriptase / chain-terminating inhibitors / 2 '-deoxyinosine 5 '-triphosphate / processivity ) , 2022 .